PierianDx will be highlighting germline features of its genomics technology platform the American College of Medical Genetics and Genomics (ACMG) annual meeting April 10-14 in Charlotte, North Carolina.
Representatives from PierianDx will be on hand in Booth 1203 demonstrating the Clinical Genomics WorkSpace (CGW), the industry’s leading integrated workspace for genomic analytics, classification, interpretation and reporting.
CGW germline testing features include phenotype-based prioritization of variants and rapid classification of variants following ACMG guidelines. PierianDx’s support for germline testing also includes Clinical Microarray (CMA), commonly used in the germline setting to evaluate complex development disorders.
PierianDx complements its germline technology with a range of support services. The company’s interpretation services involves clinical and scientific teams leveraging CGW’s patented knowledgebase to provide highly scalable and reliable clinical interpretations for inherited diseases. Interpretations by PierianDx variant scientists and medical directors are combined with machine learning within the knowledgebase comprised of million of biomedical finding to produce the most clinically actionable insight available for customers.
If you would like to learn more about PierianDx or CGW, please schedule a meeting.
